Veredus will be exhibiting at the 44th Union World Conference on Lung Health in Paris, France from 30th October till 3rd November 2013.

Come visit us at Booth 56.

Click here for more information

Veredus Laboratories has confirmed in-silico that the current VereFlu™ panel is able to detect all H7 influenza strains, including the circulating H7N9 strain in China.

Veredus Laboratories has confirmed in-silico that the current VereFlu™ panel is able to detect all H7 influenza strains, including the circulating H7N9 strain in China.

Veredus hosted its very first Veredus Tuberculosis Seminar at the Shaw Foundation Alumni House, Singapore.

Tuberculosis experts, Dr Daniela Maria Cirillo and Dr Sushil Pandey, spoke at the Seminar.

Look out for Veredus at Booth 67 at the 43rd Union World Conference on Lung Health in Kuala Lumpur, Malaysia

November 13-17, 2012

Look out for Veredus at Booth 67 at the 43rd Union World Conference on Lung Health in Kuala Lumpur, Malaysia

Veredus Launches new Lab-on-Chip, VereMTB™

Veredus Laboratories, has launched VereMTB™, a multiplexed molecular diagnostic chip capable of fast and accurate detection of Mycobacterium Tuberculosis Complex (MTBC) and its mutations, as well as 9 other clinically relevant non-tubercular mycobacterium. These mutations are responsible for resistance to multiple drugs and are reinvigorating the global spread of Tuberculosis.

Click here for more information

Veredus launches new website

Veredus Laboratories unveils a brand new image through its new website.

Veredus appoints NanoGen Teknolojileri Ltd as exclusive distributor in Turkey.

Veredus Laboratories appoints NanoGen Teknolojileri Ltd as exclusive distributor in Turkey.

Veredus Laboratories’ Avian Flu Test on STMicroelectronics’ Lab-on-Chip enters Evaluation Trial at National University Hospital

March 26, 2007

Using STMicroelectronics’ In-Check™platform, Veredus’ test specifically identifies whether a patient is infected with the Avian Flu (H5N1) or a subtype of Influenza A or B in a single test, instead of requiring many tests, as needed currently. The single-test application will be a substantial breakthrough in enabling rapid identification of the infectious agent to limit the spread of the disease and speed patients’ treatment. The chip is also capable of detecting avian flu strains that have not crossed over to humans, providing a first line of detection.

More information